J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion
- Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $132 per share, totaling about $14.6 billion, marking the largest biotechnology acquisition since early 2023.
- The deal includes Intra-Cellular's drug Caplyta, approved for schizophrenia and bipolar depression, with potential for expanded use in major depressive disorder.
- J&J CEO Joaquin Duato stated the acquisition supports the company's legacy in neuroscience and commitment to advancing care for neuropsychiatric disorders.
- Analysts view the acquisition as a strategic move for J&J, providing opportunities in the neuroscience market despite recent drug failures by competitors.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left5Leaning Right2Center7Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 36%
C 50%
14%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
